CorMedix Inc. (CRMD) Reports Q1 2026 Results

CorMedix Inc. (NASDAQ:CRMD) is one of the 10 Most Profitable Small Cap Stocks to Buy.

On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 million. The firm said DefenCath contributed $97.5 million in revenue with higher outpatient dialysis utilization and a $9.0 million favorable estimate change. The acquired Melinta portfolio added $29.9 million.

The company raised its 2026 guidance, projecting revenue between $325 million and $345 million and adjusted EBITDA to $115 million-$135 million. The corporation reported cash and short-term investments of $178.1 million as of March 31, 2026.

Chairman and CEO Joseph Todisco said CorMedix entered the year with “strong momentum” and that DefenCath “continues to exceed expectations” despite pending TDAPA expiration. He also noted progress in late-stage programs, including REZZAYO, with the company preparing an FDA submission in the second half of 2026. It targets a potential expanded launch in 2027.

CorMedix Inc. (CRMD) Reports Q1 2026 Results

CorMedix Inc. (NASDAQ:CRMD) is a pharmaceutical and medical device firm that makes and markets therapeutic solutions for the prevention and treatment of diseases and conditions.

While we acknowledge the risk and potential of CRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRMD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1